Evidence map›Paper›PMID 35633466›Full record

ReviewCurrent neurology and neuroscience reports2022

Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1.

Richard A Manfready, Christopher B Forsyth, Robin M Voigt, Deborah A Hall, Christopher G Goetz, Ali Keshavarzian

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06460038 (Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06460038 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation

TypeinterventionalSponsorCedar Valley Digestive Health CenterRan2025 to 2027Enrolled30ConditionsSynucleinopathy, Parkinson's DiseaseArmsTenapanor, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Parkinson Disease and the Gut: A Primer for Gastroenterologists.The American journal of gastroenterology · 2025
    Review
  4. Gut: The gate and key to brain.Chinese medical journal · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. The gastrointestinal tract and Parkinson's disease.Frontiers in cellular and infection microbiology · 2023
    Review
  11. Gut Microbes and Neuropathology: Is There a Causal Nexus?Pathogens (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Richard A ManfreadyDepartment of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA.
Christopher B ForsythDepartment of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA.
Robin M VoigtDepartment of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA.
Deborah A HallDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Christopher G GoetzDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Ali KeshavarzianDepartment of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL, USA. Ali_Keshavarzian@rush.edu.
Rush University Medical Center · US

Funding

Microbiota-Brain Axis in Alzheimer's Disease: MIND Diet-Induced EffectsR01AG056653 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI VOIGT-ZUWALA, ROBIN M · 2018 to 2022
$3.2M
NIA NIH HHS R01 AG056653
6 · The paper itself

Abstract

purpose of reviewDefective gut-brain communication has recently been proposed as a promoter of neurodegeneration, but mechanisms mediating communication remain elusive. In particular, the Parkinson's disease (PD) phenotype has been associated with both dysbiosis of intestinal microbiota and neuroinflammation. Here, we review recent advances in the PD field that connect these two concepts, providing an explanation based on enteroendocrine signaling from the gut to the brain. RECENT

findingsThere have been several recent accounts highlighting the importance of the microbiota-gut-brain axis in PD. The objective of this review is to discuss the role of the neuroendocrine system in gut-brain communication as it relates to PD pathogenesis, as this system has not been comprehensively considered in prior reviews. The incretin hormone glucagon-like peptide 1 (GLP-1) is secreted by enteroendocrine cells of the intestinal epithelium, and there is evidence that it is neuroprotective in animal models and human subjects with PD. Agonists of GLP-1 receptors used in diabetes appear to be useful for preventing neurodegeneration. New tools and models have enabled us to study regulation of GLP-1 secretion by intestinal microbiota, to understand how this process may be defective in PD, and to develop methods for therapeutically modifying disease development or progression using the enteroendocrine system. GLP-1 secretion by enteroendocrine cells may be a key mediator of neuroprotection in PD, and new findings in this field may offer unique insights into PD pathogenesis and therapeutic strategies.

Indexed as

Brain-Gut AxisGlucagon-Like Peptide 1Neurosecretory SystemsParkinson DiseaseAnimalsBrainDysbiosisHumansGlucagon-Like Peptide 1EnteroendocrineGlucagon-like peptide 1Gut-brain communicationParkinson’s disease

Identifiers

PMID35633466
OpenAlexW4281913862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.